Doz

Budesonide + formoterol

بودزوناید + فورموترول (سیمبیکورت)

⚠ Unverified

🫁 Respiratory SystemICS + LABA

🤰 Pregnancy:Use with caution🤱 Breastfeeding:Use with caution👶 Children:Use with caution👴 Older adults:Use with caution 🇮🇷 Registered in Iran⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA021929ATC R03AK07

Market / country: 🇺🇸 USA

Symbicort (US)

🧮 Dose calculator

Asthma and chronic lung disease (reversible airflow obstruction) · Regimen source: FDA Symbicort · 2.2

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

  • ⛔ Primary treatment of status asthmaticus or acute asthma/COPD episodes. FDA Symbicort · 4

Warnings

Formulations

  • 80 mcg budesonide / 4.5 mcg formoterol per actuation — inhaler 🇺🇸 USA FDA Symbicort · 3

👥 Special populations

  • 🤰 PregnancyUse with caution

    Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Symbicort · 8.1

    “Risk Summary There are no adequate and well-controlled studies of SYMBICORT or one of its individual components, formoterol fumarate, in pregnant women; however studies are available for the other component budesonide.”
  • 🤱 BreastfeedingUse with caution

    Label: use with caution while breastfeeding; see the label text. FDA Symbicort · 8.2

    “Risk Summary There are no available data on the effects of SYMBICORT, budesonide or formoterol fumarate on the breastfed child or on milk production.”
  • 👶 ChildrenUse with caution

    The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Symbicort · 8.4

    “Safety and effectiveness of SYMBICORT in asthma patients 12 years of age and older have been established in studies up to 12 months.”
  • 👴 Older adultsUse with caution

    Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Symbicort · 8.5

    “As with other products containing beta 2 -agonists, special caution should be observed when using SYMBICORT in geriatric patients who have concomitant cardiovascular disease that could be adversely affected by beta 2 -agonists.”
  • ⚥ Females & males of reproductive potentialNo data

    The source for this drug has no section for this group.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

🔗 Similar drugs

Doz is only a support tool and does not replace clinical judgment or official sources. Check every dose against the original source before prescribing. About & disclaimer · Sources

Inspired by the Saphira project; part of the content is taken from it.

Contact and correction requests — Telegram: @cenaav